The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease

Vaccine. 2006 Jun 5;24(23):5027-35. doi: 10.1016/j.vaccine.2006.03.064. Epub 2006 Apr 18.

Abstract

Formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) induces a poorly understood immunopathological response that leads to disease enhancement upon RSV infection of vaccinees. In the cotton rat model, inclusion of monophosphoryl lipid A (MPL) in the FI-RSV formulation was found to mitigate the lung pathology associated with vaccine-enhanced disease. Here we report that the protective effect of MPL on FI-RSV vaccine-enhanced disease is associated with a dramatic reduction in levels of Th1- and Th2-type cytokines and chemokines normally elicited in response to RSV challenge. Our data illustrate the complexity of proinflammatory response elicited by FI-RSV vaccination and RSV infection and the potential importance of MPL in modifying this response.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Cytokines / antagonists & inhibitors*
  • Cytokines / immunology*
  • Cytokines / metabolism
  • Gene Expression Regulation
  • Lipid A / analogs & derivatives*
  • Lipid A / pharmacology
  • Lung / metabolism
  • Lung / pathology
  • Respiratory Syncytial Virus Vaccines / adverse effects*
  • Respiratory Syncytial Virus Vaccines / immunology*
  • Respiratory Syncytial Viruses / immunology*
  • Sigmodontinae / immunology
  • Toll-Like Receptor 4 / agonists*

Substances

  • Adjuvants, Immunologic
  • Cytokines
  • Lipid A
  • Respiratory Syncytial Virus Vaccines
  • Toll-Like Receptor 4
  • monophosphoryl lipid A